Prior to moving to Arizona, Dr. Gordon worked and trained at major academic institutions, including the Indiana University School of Medicine, Memorial Sloan-Kettering Cancer Center, and the University of Chicago Hospital and Clinics. Dr. Gordon is a respected innovator and leader in a variety of biomedical research areas and has helped develop multiple new cancer treatments. He is a board-certified specialist in both solid and blood cancers, approaching his work from a unique perspective: not only as a physician-scientist, but also as a patient, having been diagnosed and treated in 2021 for early-stage pancreatic cancer. His overarching goals are to promote the best science and to provide the best care for patients. During his time at HonorHealth, he also has served in key leadership capacities for the Arizona Center for Cancer Care, Arizona State University, the University of Arizona Cancer Center, and the University of Arizona College of Medicine-Phoenix.
Michael S. Gordon, M.D., F.A.S.C.O.
Biography
- Fellow, Society of Clinical Oncology
Research Interests & Focus
Dr. Michael S. Gordon has served as the Chief Medical Officer of the HonorHealth Research Institute since May 2021, helping supervise the Research Institute’s five major divisions including: Oncology, Cardiovascular, Bariatric/GI, Neuroscience and Multispecialty. He also is the Research Director of the Multispecialty Research Division, which includes pulmonology, rheumatology, infectious disease (including COVID-19), and other emerging areas of biomedical research. As part of the medical staff at HonorHealth since 2000, Dr. Gordon has served on numerous committees serving the Research Institute’s Clinical Trials Programs, including Chairperson of the HonorHealth Institutional Review Board (HIRB). Dr. Gordon is an author of more than 175 peer-reviewed academic papers published in scientific journals. He has written 33 scientific book chapters and reviews, and presented more than 100 scientific abstracts. Dr. Gordon’s research interests include soft tissue sarcoma, rare cancers, and urologic cancers such as prostate cancer and kidney cancer.